2 things to say your post before wishing everyone here a happy 4th:
1) The CTLM already has been clinically proven to be more than 90% more effective and sensitive to the detection of cancer THROUGH dense tissue and implants (no other technology in the world can do this, hence why Bioscan, Inc. has paid them royalty fees for their CT patents and will be paying them royalty fees for any products sold using their technology. LILA technology is what they are developing, and has been under development for 6 years. Long story short IMDS's technology is already expanding to other markets. It also is helpful to know that the CTLM alone has 35 individual patents, 20 USA and 15 Intl. that do not expire until the year 2020.
2) The company already has the machine IN USE in ]16 different countries and is responsible for 25,000 scans as of last March. Shimadzu Medical and Mareen Group signed on as distributors just last May, to add to the list of their 16 international distributors already. And Shimadzu updated their website just two weeks ago CONFIRMING the business relationship between the two companies...that's first HUGE if you research Shimadzu, and secondly that throws any "scam" arguments out the window.
If you look at Shimadzu Corp.'s annual filing for fiscal year 2011, they grossed US$1.2 billion, and had US$375 million in cash as of last March. Shimadzu is an international comglomerate.
So long story short...you already have international use and exposure, and clinical proof the CTLM is superior to all current technology, and with LILA, count on IMDS's GLOBAL monopoly extending into multiple sectors. Major market bubbles coming out of this company.
Market Data 
Markets 
AI
